Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570503 · ClinicalTrials.gov registry record · Phase 4
Postoperative Pain Control After Periarticular Injection During Total Knee Arthroplasty
A Phase 4 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT02570503: Clinical Trial Phase 4 study, sponsored by Virginia Commonwealth University.
NCT02570503 is a Phase 4 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 64 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02570503, a Phase 4 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study will evaluate the use of a local injection around the knee (periarticular) during total knee replacement (TKR) surgery to see if it reduces postoperative pain levels. The injection is a combination of various medications which are thought to reduce pain levels. Approximately 128 patients will participate in this study, half of the patients will receive this injection during surgery and the other half will receive a saline (salt water) injection. Pain scores after the surgery will be compared between the two groups. All patients will also receive a long-acting (24 hours) morphine injection during surgery. The hypothesis is that those participants receiving intrathecal Duramorph and local periarticular injections will have improved pain scores and reduced narcotic use when compared with intrathecal Duramorph alone at 48 hours postoperatively.
Primary Outcome
Patient's pain scores will be measured with the UPAT scale which ranges from 0 (no pain) to 10 (severe pain) This is measured hourly while the patient is awake after the surgery.
Interventions
- DRUG Ketorolac
- DRUG Epinephrine
- DRUG Ropivacaine
- DRUG 0.9% sodium chloride
- DRUG Clonidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-10 |
| Est. Completion | 2021-02-11 |
| Phase | Phase 4 |
Why NCT02570503 stopped before completion
NCT02570503 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 5 interventions - of which Ketorolac is the first listed.
NCT02570503 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02570503 about?
NCT02570503 is a clinical study titled "Postoperative Pain Control After Periarticular Injection During Total Knee Arthroplasty". This study will evaluate the use of a local injection around the knee (periarticular) during total knee replacement (TKR) surgery to see if it reduces postoperative pain levels. The injection is a combination of various medications which are thought to reduce pain levels. Approximately 128 patients...
What is the current status of trial NCT02570503?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2015-10. Estimated completion is 2021-02-11.
What interventions are being tested in trial NCT02570503?
The interventions under investigation include: Ketorolac (DRUG), Epinephrine (DRUG), Ropivacaine (DRUG), 0.9% sodium chloride (DRUG), Clonidine (DRUG).
Who is sponsoring clinical trial NCT02570503?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02570503's enrollment target sits among peer trials
64 1098th of 2000 higher than 895 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia